KUZEY KIBRIS YETİŞKİNLERİNDE D VİTAMİNİ VE ÜRİK ASİT ARASINDAKİ İLİŞKİ: BİRİNCİ ÖN HAZIRLIK RAPORU

Yıl 2022, Cilt: 85 Sayı: 4, 564 - 571, 28.10.2022

Mehtap Tınazlı Nuriye Sancar , Meryem Güvenir , Deniz Granit Semavi

https://doi.org/10.26650/IUITFD.1078093

Öz

Amaç: Kuzey Kıbrıs için hiperürisemi ile 25-OH-VIT D eksikliği arasındaki
ilişki hakkında veri yoktur. Bu çalışmanın amacı serum ürik
asit (SUA) ile 25-OH-VIT D arasındaki ilişkiyi değerlendirmektir.
Gereç ve Yöntem: Kuzey Kıbrıs’ta yaşları 18-75 arasında değişen
356 yetişkin üzerinde kesitsel bir çalışma yapılmıştır. Hastaların
sosyodemografik bilgileri, klinik ve biyokimyasal özellikleri, beslenme
alışkanlıkları ve yaşam tarzı tercihleri kaydedildi. Tüm hastalarda
biyokimyasal parametreler değerlendirildi. Veriler Ki-kare
testi, Student t testi ve uygun şekilde ANOVA ile analiz edildi.
Ayrıca 25-OH Vitamin D grupları ile diğer değişkenler arasındaki
ilişki için Gama korelasyon katsayısı hesaplandı.
Bulgular: Hastalar arasında 25-OH-VIT D eksikliği prevalansı
%55,9 (12,86±4,63 ng/mL), 25-OH-VIT D yetmezliği prevalansı
(23,44±2,38 ng/mL) %27 idi ve 25-OH-VIT D düzeyleri hastaların
sadece %17,1’inde yeterliydi (36,01±5,83 ng/mL). ANOVA
sonuçları, 25-OH-VIT D grupları arasında hem erkek hem de
kadın hastalar için istatistiksel olarak anlamlı SUA farklılıkları
gösterdi. Gama korelasyon katsayısı değerlerine göre, 25-OH
Vitamin D düzeyleri SUA ile anlamlı olarak negatif korelasyon
gösterdi.
Sonuç: Çalışmamızda Kuzey Kıbrıs erişkinlerinde 25-OH-VIT D
eksikliği ve yetersizliği prevalansının yüksek olduğu gösterildi ve
SUA düzeyleri ile 25-OH-VIT D arasında anlamlı bir ilişki bulundu.
Sonuç olarak, hem D vitamini takviyesi hem de ürikasit düşürücü
tedaviler, hastaları gelecekteki aterosklerotik hastalıklara karşı
korumada önemlidir.

Anahtar Kelimeler

Kuzey Kıbrıs, Vitamin D, ürik asit, prevalans, ateroskleroz

ASSOCIATION BETWEEN VITAMIN D AND URIC ACID AMONG NORTH CYPRUS ADULTS: FIRST PRELIMINARY REPORT

Öz

Objective: The aim of the study is to evaluate the association
between serum uric acid (SUA) and 25-OH Vitamin D (25-OH-VIT
D). There is no data about the association between hyperuricemia
and 25-OH-VIT D deficiency for North Cyprus.
Material and Methods: A cross-sectional study was performed
on 356 adults aged between 18-75 years in the North
Cyprus. Patients socio-demographic information, clinical and
biochemical characteristics, eating habits, and lifestyle choices
were recorded. Biochemical parameters were evaluated in all
patients. Data were analysed by Chi-square test, Student’s t
test, and ANOVA, as appropriate. Also, the Gamma correlation
coefficient was calculated for the relationship between 25-OH
Vitamin D groups and the other variables.
Results: The prevalence of 25-OH-VIT D deficiency was 55.9%
among the patients (12.86±4.63 ng/mL), the prevalence of
25-OH-VIT D insufficiency (23.44±2.38 ng/mL) was 27%, and
25-OH-VIT D levels were sufficient in only 17.1% of the patients
(36.01±5.83 ng/mL). The ANOVA results indicated statistically
significant differences SUA for both male and female patients
between the 25-OH-VIT D groups. According to the Gamma
correlation coefficient values, 25-OH Vitamin D levels were significantly
negatively correlated with SUA.
Conclusion: In our study indicated a high prevalence of 25-OHVIT
D deficiency and insufficiency in North Cyprus adults and
we have found a significant association between SUA levels and
25-OH-VIT D. As a result, both vitamin D supplementation and
uric acid-lowering therapies are important in protecting patients
against future atherosclerotic diseases.

Anahtar Kelimeler

North Cyprus, Vitamin D, uric acid, prevalence, atherosclerosis

Kaynakça

• 1. Alemzadeh R, Kichler J. Uric acid-induced inflammation is mediated by the Parathyroid Hormone:25-Hydroxyvitamin D ratio in obese adolescents. Metab Syndr Relat Disord 2016;14(3):167-74. [CrossRef] google scholar
• 2. Tınazlı M, Cerit L. Hyperuricemia and Fragmented QRS. 14th International Congress of update in cardiology and cardiovascular surgery. Am J Cardiol 2018;121(8):67-8. [CrossRef] google scholar
• 3. Charoenngam N, Ponvilawan B, Ungprasert P. Vitamin D insufficiency and deficiency are associated with a higher level of serum uric acid: A systematic review and metaanalysis. Mod Rheumatol 2020;30(2):385-90. [CrossRef] google scholar
• 4. Van der Pligt P, Willcox J, Szymlek-Gay EA, Murray E, Worsley A, Daly RM. Associations of Maternal Vitamin D Deficiency with Pregnancy and Neonatal Complications in Developing Countries: A Systematic Review. Nutrients 2018;10(5):640. [CrossRef] google scholar
• 5. Saponaro F, SabaA , Zucchi R. An update on vitamin D metabolism. Int J Mol Sci 2020;21(18):6573. [CrossRef] google scholar
• 6. Charoenngam N, Holick MF. Immunologic effects of vitamin D on human health and disease. Nutrients 2020;12(7):2097. [CrossRef] google scholar
• 7. Isnuwardana R, Bijukchhe S, Thadanipon K, Ingsathit A, Thakkinstian A. Association Between Vitamin D and Uric Acid in Adults: A Systematic Review and Meta-Analysis. Horm Metab Res 2020;52:732-41. [CrossRef] google scholar
• 8. Bonakdaran S, Varasteh AR. Correlation between serum 25 hydroxy vitamin D3 and laboratory risk markers of cardiovascular diseases in type 2 diabetic patients. Saudi Med J 2009;30(4):509-14. google scholar
• 9. Chien KL, Hsu HC, Chen PC, Lin HJ, Su TC, Chen MF et al. Total 25-hydroxyvitamin D concentration as a predictor for all-cause death and cardiovascular event risk among ethnic Chinese adults: A cohort study in a Taiwan community. PLoS One 2015;10(3):e0123097. [CrossRef] google scholar
• 10. Faridi KF, Lupton JR, Martin SS, Banach M, Quispe R, Kulkarni K et. al. Vitamin D deficiency and nonlipid biomarkers of cardiovascular risk. Arch Med Sci 2017;13(3):732-7. [CrossRef] google scholar
• 11. Sipahi S, Acikgoz SB, Genc AB, Yıldırım M, Solak Y, Tamer A. The association of vitamin d status and vitamin d replacement therapy with glycemic control, serum uric acid levels, and microalbuminuria in patients with type 2 diabetes and chronic kidney disease. Med Princ Pract 2017;26(2):146-51. [CrossRef] google scholar
• 12. Vallianou N, Bountziouka V, Akalestos T, Evangelopoulos A, Vogiatzakis E, Bonou M. et. al. Vitamin D status and health correlates among apparently healthy participants in an urban, sunny region. Cent Eur J Public Health 2012;20(4):262-9. [CrossRef] google scholar
• 13. Chen W, Roncal-Jimenez C, Lanaspa M, Gerard S, Chonchol M, Johnson RJ, et al. Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. Metab Clin Exp 2014;63(1):150-60. [CrossRef] google scholar
• 14. Türkiye Endokrinoloji ve Metabolizma Derneği. In:Osteoporoz ve Metabolik Kemik Hastalıkları Tanı ve Tedavi Kılavuzu. Vitamin D Eksikliği. 15.Baskı. Ankara 2020;119-28. google scholar
• 15. Fan W, Huang Y, Zheng H, Li S, Li Z, Li Yuan et al. Ginsenosides for the treatment of metabolic syndrome and cardiovascular diseases: Pharmacology and mechanisms. Biomed Pharmacother 2020;132:110915. [CrossRef] google scholar
• 16. Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA, Vázquez C, Escobar-Morreale HF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clinical Nutrition. 2007;26(5):573-80. [CrossRef] google scholar
• 17. Latic N, Erben RG. Vitamin D and cardiovascular disease, withemphasis on hypertension, atherosclerosis, and heart failure. Int J Mol Sci 2020;21(18):6483. [CrossRef] google scholar
• 18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. Circulation. 2002;106(25):3143-421. [CrossRef] google scholar
• 19. Tınazlı M, Becer E, Sancar N, Özgöl Y. Prevalence of Metabolic syndrome in routine check-up programme in Cyprus. The American Journal of Cardiology. 2018; 121(8). [CrossRef] google scholar
• 20. Abbasian M, Ebrahimi H, Delvarianzadeh M, Norouzi P, Fazli M. Association between serum uric asit (SUA) levels and metabolic syndrome (MetS) components in personnel of Shahroud University of Medical Sciences. Diabetes&Metabolic Syndrome: Clinical Research&Reviews 2016;10(3):132-136. [CrossRef] google scholar
• 21. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007;49(5):1063-9. [CrossRef] google scholar
• 22. Tomson J, Hin H, Emberson J, Kurien R, Lay M, Cox J, et al. Effects of vitamin D on blood pressure, arterial stiffness, and cardiac function in older people after 1 year: BEST–D (Biochemical Efficacy and Safety Trial of Vitamin D). J Am Heart Assoc. 2017;6(10):e005707. [CrossRef] google scholar
• 23. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin d deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96(7):1911-30. [CrossRef] google scholar
• 24. Krul-Poel YH, vanWijland H, Stam F, Boekel E, Lips P, Simsek S. Studyprotocol: a randomised placebo controlled clinical trial to study the effect of vitamin D supplementation on glycaemic control in type 2 diabetes mellitus SUNNY trial. BMC Endocr Disord 2014;14:59. [CrossRef] google scholar
• 25. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J ClinNutr 2000;72(3): 690-3. [CrossRef] google scholar
• 26. Aasheim ET, Hofso D, Hjelmeseth J, Birkeland KI, Bohmer T. Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr 2008;87(2):362-9. [CrossRef] google scholar
• 27. Valer-Martinez A, Martinez JA, Sayon-Orea. C, Galvano F, Grosso G, Bes-Rastrollo M. Vitamin D and cardio-metabolic risk factors in overweight adults: an overview of evidence. Curr Pharm Des 2019;25(22):2407-20. [CrossRef] google scholar
• 28. Wimalawansa SJ. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. J Steroid Biochem Mol Biol 2018;175:177-89. [CrossRef] google scholar